Altimmune (NASDAQ:ALT) Trading Up 16.1% – Still a Buy?

23 Jan 2026, 12:22 by Renee Jackson · The Cerbat Gem

Altimmune, Inc. (NASDAQ:ALT – Get Free Report)’s share price rose 16.1% during mid-day trading on Friday . The stock traded as high as $5.94 and last traded at $6.2470. Approximately 2,101,752 shares traded hands during trading, a decline of 62% from the average daily volume of 5,556,123 shares. The stock had previously closed at $5.38.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on ALT shares. Citigroup reissued a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Citizens Jmp decreased their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $16.60.

View Our Latest Stock Analysis on ALT

Altimmune Price Performance

The company’s 50-day moving average is $4.54 and its 200-day moving average is $4.11. The firm has a market capitalization of $600.48 million, a price-to-earnings ratio of -5.40 and a beta of 0.04. The company has a debt-to-equity ratio of 0.08, a current ratio of 17.18 and a quick ratio of 17.18.

Altimmune (NASDAQ:ALT – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. On average, research analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Insider Activity

In other Altimmune news, Director Jerome Benedict Durso purchased 12,500 shares of Altimmune stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average price of $4.13 per share, with a total value of $51,625.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director John Gill acquired 12,500 shares of the company’s stock in a transaction on Tuesday, December 23rd. The shares were acquired at an average price of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares in the company, valued at $51,250. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 30,527 shares of company stock worth $125,278. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ALT. Vanguard Group Inc. boosted its holdings in shares of Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after buying an additional 1,206,514 shares during the period. Two Sigma Investments LP raised its stake in shares of Altimmune by 356.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after buying an additional 1,559,562 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Altimmune by 13.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares in the last quarter. Federated Hermes Inc. grew its position in Altimmune by 387.7% in the second quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock worth $3,543,000 after buying an additional 727,731 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Altimmune by 155.2% during the second quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock valued at $2,771,000 after purchasing an additional 435,467 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

(Get Free Report)

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.